1. Home
  2. FT vs XBIT Comparison

FT vs XBIT Comparison

Compare FT & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.05

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.47

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
XBIT
Founded
1988
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
75.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FT
XBIT
Price
$8.05
$2.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.7K
21.5K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.37
$2.09
52 Week High
$8.35
$3.61

Technical Indicators

Market Signals
Indicator
FT
XBIT
Relative Strength Index (RSI) 41.49 48.92
Support Level $8.02 $2.15
Resistance Level $8.06 $2.69
Average True Range (ATR) 0.08 0.08
MACD -0.02 -0.01
Stochastic Oscillator 17.86 24.69

Price Performance

Historical Comparison
FT
XBIT

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: